https://www.selleckchem.com/pr....oducts/SB-202190.htm
04, median event free survival 22.8 vs. 5.6 months; P=0.04, median OS 124 vs. 22.5 months). Conclusions We thus propose that hyperactive Ras signaling confers inferior survival in high-risk pediatric acute leukemia and that Ras pathways should be molecularly characterized to inform clinical decision making and to identify patients for experimental clinical trials and RAS-targeted therapy. 2020 Translational Pediatrics. All rights reserved.Background This study aims to investigate the efficacy and safety of umbilical cord blood transpl
Curtir
Comentario
Compartilhar
